Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wulf H Utian

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Medicine|June 28, 2023
Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind StudyJean Michel Foidart, Krzysztof Simon, Wulf H Utian, et al.
Obstetrics and Gynecology|February 3, 2004
Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogensWulf H Utian, Samuel A Lederman, Brenda M Williams, et al.
Menopause (New York, N.Y.)|February 23, 2007
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safetyDale W Stovall, Wulf H Utian, Margery L S Gass, et al.
Menopause (New York, N.Y.)|September 19, 2015
Use of compounded hormone therapy in the United States: report of The North American Menopause Society SurveyMargery L S Gass, Cynthia A Stuenkel, Wulf H Utian, et al.
Menopause (New York, N.Y.)|February 22, 2023
A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of lifeUlysse Gaspard, Mélanie Taziaux, Maud Jost, et al.
Menopause (New York, N.Y.)|June 24, 2009
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisJoAnn V Pinkerton, David F Archer, Wulf H Utian, et al.
Menopause (New York, N.Y.)|November 23, 2011
The Chinese Utian Quality of Life Scale for women around menopause: translation and psychometric testingPing-Ling Chen, Hsiang-Tai Chao, Kuei-Ru Chou, et al.
Menopause (New York, N.Y.)|May 8, 2020
A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safetyUlysse Gaspard, Mélanie Taziaux, Marie Mawet, et al.
Menopause (New York, N.Y.)|June 23, 2009
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenDavid F Archer, JoAnn V Pinkerton, Wulf H Utian, et al.
Bone|December 22, 2006
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massRobert R Recker, David Kendler, Christopher P Recknor, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Medicine|June 28, 2023
Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind StudyJean Michel Foidart, Krzysztof Simon, Wulf H Utian, et al.
Obstetrics and Gynecology|February 3, 2004
Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogensWulf H Utian, Samuel A Lederman, Brenda M Williams, et al.
Menopause (New York, N.Y.)|February 23, 2007
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safetyDale W Stovall, Wulf H Utian, Margery L S Gass, et al.
Menopause (New York, N.Y.)|September 19, 2015
Use of compounded hormone therapy in the United States: report of The North American Menopause Society SurveyMargery L S Gass, Cynthia A Stuenkel, Wulf H Utian, et al.
Menopause (New York, N.Y.)|February 22, 2023
A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of lifeUlysse Gaspard, Mélanie Taziaux, Maud Jost, et al.
Menopause (New York, N.Y.)|June 24, 2009
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisJoAnn V Pinkerton, David F Archer, Wulf H Utian, et al.
Menopause (New York, N.Y.)|November 23, 2011
The Chinese Utian Quality of Life Scale for women around menopause: translation and psychometric testingPing-Ling Chen, Hsiang-Tai Chao, Kuei-Ru Chou, et al.
Menopause (New York, N.Y.)|May 8, 2020
A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safetyUlysse Gaspard, Mélanie Taziaux, Marie Mawet, et al.
Menopause (New York, N.Y.)|June 23, 2009
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenDavid F Archer, JoAnn V Pinkerton, Wulf H Utian, et al.
Bone|December 22, 2006
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massRobert R Recker, David Kendler, Christopher P Recknor, et al.
Pageof 4